Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 739-746

  Pfennigsdorf, Stefan ^a   Ramez, Osman ^b   von Kistowski, Gerrit ^c   Mäder, Birgit ^a   Eschstruth, Peter ^d   Froböse, Michael ^e   Thelen, Ulrich ^f   Spraul, Christoph ^g   Schnober, Dietmar ^h   Cooper, Hazel ⁱ   Laube, Thomas ^j  

^a Polch Ophthalmology Practice ^*  (Germany)

^b Buxtehude Ophthalmology Practice   (Germany)

^c Nürnberg Ophthalmology Practice   (Germany)

^d Ophthalmology Practice   (Germany)

^e Ophthalmology Practice   (Germany)

^f Group Practice   (Germany)

^g Group Practice   (Germany)

^h Ophthalmology Practice   (Germany)

ⁱ ALLERGAN PLC   (United States)

^j Group Practice   (Germany)

more..

Author keywords

Bimatoprost 0.01 ; Glaucoma; Intraocular pressure; Observational; Ocular hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; PROSTAGLANDIN DERIVATIVE; TIMOLOL;

ABNORMAL SENSATION; ADULT; ADVERSE OUTCOME; ARTICLE; ASTHMA; BLURRED VISION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; EYE IRRITATION; EYE PAIN; EYELID DISEASE; EYELID ERYTHEMA; FEMALE; GERMANY; HEADACHE; HUMAN; HYPEREMIA; HYPERPIGMENTATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION DISORDER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84863466423     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S31330     Document Type: Article

References (16)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-851.
2. Quigley HA. Glaucoma. Lancet. 2011;377:1367-1377.
3. Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126:1030-1036.
4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
5. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd ed. Savona, Italy: Editrice Dogma; 2008.
6. Advanced Glaucoma Intervention Study. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429-440.
7. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667-673.
8. van der Valk V, Webers CA, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009;62:1279-1283.
9. Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 2007;23: 601-608.
10. Wirta D, Van Denburgh AM, Weng E, et al. Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials. Clin Ophthalmol. 2011;5:759-765.
11. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145-152.
12. Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149:661-671.
13. Allergan Ltd. Lumigan prescribing information. Available at: http://www. allergan.com/assets/pdf/lumigan_pi.pdf. Accessed March 28, 2012.
14. Williams RD, Cohen JS, Gross RL, et al. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol. 2008;92:1387-1392.
15. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
16. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953-961.